Closed kokyriakidis closed 2 years ago
Hi, we presented some tumour-only benchmarks in the Nature Biotechnology paper. We don't compare to Mutect2 as this tool doesn't officially support tumour-only calling - it doesn't try to classify germline and somatic variants.
Hi!
Do you have any recent benchmarks regarding Tumor only variant calling (vs Mutect)?
Thanks, Konstantinos